FOLX Health expressly includes nonhormonal medicines in its perimenopause and menopause service. Its LGBTQIA+ focus also brings clinical care together with community resources and support. Those features may matter when evaluating a service, but they answer different questions from the identity, evidence and safety of a proposed medicine.
Reviewed September 29, 2026, this assessment considers the menopause-care description, membership information, visit charges and cancellation policy. It does not assess a patient’s experience of affirming care or confirm a particular prescription. The purpose is to separate what the service offers from what a clinician would still need to establish about the treatment goal and the individual proposal.
The menopause page supports an actual nonhormonal offering
FOLX’s care description says it offers nonhormonal medicines when hormone therapy is not the right approach, mentioning symptoms such as hot flashes and vaginal dryness. It does not identify one specific preparation that treats both concerns or confirm a formulary for every patient. Our Joi review concerns a different boundary: a confirmed menopause service with an unverified nonhormonal menu. FOLX is more explicit about the category, but that additional detail is not a clinical ranking. The medicine, formulation, intended use and relevant medical history still need to be brought together by the treating professional.
Separate a symptom goal from assumptions about gender or treatment
The FOLX menopause explanation discusses care for LGBTQIA+ people and the different contexts in which menopause concerns may arise. Its broad scope should not imply that every person has the same anatomy, treatment history or preferences. A consultation needs the information relevant to the actual concern, rather than assumptions drawn from identity alone. The visit-goals guide helps make that concern clear without producing a personal decision tree. This review does not infer which hormones someone uses, whether they should stop existing care or which nonhormonal medicine would fit. Those remain individualized clinical questions.
Mental-health treatment and hot-flash treatment are not interchangeable uses
FOLX’s primary-care description includes prescribing certain medicines for mental-health conditions. That is not proof that any such medicine is proposed for menopause symptoms, or that every use has the same approval status. FDA’s off-label resource explains why the condition being treated is part of the regulatory question. The medicine-family guide provides background for asking about the actual proposal. A familiar medication name should lead to a clearer discussion of purpose and evidence, not an instruction to repurpose an existing prescription or combine treatments without the prescriber’s review.
Community resources should not inherit a medicine’s evidence
FOLX describes peer support and educational resources within its membership, alongside access to clinical professionals. Those are distinct services. The 2023 professional evidence review evaluates specified vasomotor interventions rather than a provider’s overall community experience. Satisfaction with a service therefore cannot be used as proof that a particular nonhormonal medicine reduces hot flashes through that platform. Our Maven assessment examines another model combining consultations and support. Compare who does the clinical work and which outcome is being claimed, while leaving the personal value of community participation to the individual.
The annual figure pays for membership, with clinical services extra
The membership article, originally dated August 2023 and still publicly available, displays $39.99 monthly or $299 paid yearly; its opening also describes the annual option as $25 per month. Those are membership figures, not a complete menopause-care price. The clinical-services page lists a $159 initial thirty-minute visit, $79 fifteen-minute follow-up and $129 therapy session, with visits, tests and medicines otherwise separately paid or subject to relevant insurance. Availability and coverage vary by service. We have not selected an agreement, so the dated public figures should be confirmed together rather than converted into a guaranteed personal annual total. The same primary-care page distinguishes talk therapy availability in selected states from broader virtual primary care. Its separate therapy price should not be read as proof that such a visit is available everywhere or is required for menopause care. A clinical referral, membership access and the ability to book a particular professional are different parts of the arrangement, each requiring confirmation for the service being considered.
Membership cancellation and appointment cancellation use different rules
The membership policy allows account cancellation and message-assisted requests, with at least seventy-two hours before billing required for a message request. For yearly membership, the account cancellation control appears six weeks before renewal; earlier assistance can be requested. Access continues through the paid period and membership fees already paid are not refunded. Remaining laboratory or insurance balances may still be billed. Separately, the visit explanation says appointments are paid when scheduled, missed visits are not refunded, and cancellation more than twenty-four hours beforehand qualifies for a refund. Cancelling membership does not automatically resolve a scheduled appointment or a clinical continuity question. Compare the Maven package discussion when distinguishing a recurring access fee from a fixed number of clinical encounters.
The remaining decision needs a specific clinical proposal
FOLX’s menopause service establishes a relevant setting that explicitly includes nonhormonal treatment. The actual medicine and its use remain unconfirmed for an individual, as do the complete price and local availability. A useful response from the service would identify the clinician, proposed treatment purpose, relevant safety responsibilities and separately billed services. That explanation can then be considered alongside the membership terms, rather than using membership access as evidence of a guaranteed prescription. This review supplies no regimen, interaction clearance or forecast of symptom improvement; it identifies what the public offer documents and what still requires a personal clinical conversation.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- FOLX: Perimenopause and menopause supportOfficial LGBTQIA+ clinical service description with nonhormonal medication category; specific product and indication unconfirmed · Checked 2026-09-29
- FOLX: What can a clinician help with?Official clinical service, published visit charges and appointment cancellation terms; not personal availability · Checked 2026-09-29
- FDA: Understanding unapproved use of approved drugsFederal explanation distinguishing an approved medicine from an unapproved use; not a personal recommendation · Checked 2026-09-29
- FOLX: What is a membership?Official membership explainer dated August 2023 as currently accessible; monthly versus annual billed amounts, services extra · Checked 2026-09-29
- The Menopause Society: 2023 nonhormone therapy position statementPubMed primary professional abstract; vasomotor-symptom evidence categories, dated 2023 and not provider-specific efficacy or later-drug approval · Checked 2026-09-29
- FOLX: Membership cancellation policyOfficial membership notice, annual account control timing, no membership refunds and remaining bills; separate appointment cancellation terms · Checked 2026-09-29